Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
In situ profiling reveals metabolic alterations in the tumor microenvironment of ovarian cancer after chemotherapy.
Corvigno S, Badal S, Spradlin ML, Keating M, Pereira I, Stur E, Bayraktar E, Foster KI, Bateman NW, Barakat W, Darcy KM, Conrads TP, Maxwell GL, Lorenzi PL, Lutgendorf SK, Wen Y, Zhao L, Thaker PH, Goodheart MJ, Liu J, Fleming N, Lee S, Eberlin LS, Sood AK. Corvigno S, et al. Among authors: bayraktar e. NPJ Precis Oncol. 2023 Nov 3;7(1):115. doi: 10.1038/s41698-023-00454-0. NPJ Precis Oncol. 2023. PMID: 37923835 Free PMC article.
Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells.
Kanlikilicer P, Rashed MH, Bayraktar R, Mitra R, Ivan C, Aslan B, Zhang X, Filant J, Silva AM, Rodriguez-Aguayo C, Bayraktar E, Pichler M, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G. Kanlikilicer P, et al. Among authors: bayraktar r, bayraktar e. Cancer Res. 2016 Dec 15;76(24):7194-7207. doi: 10.1158/0008-5472.CAN-16-0714. Epub 2016 Oct 14. Cancer Res. 2016. PMID: 27742688 Free PMC article.
Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs.
Rashed MH, Kanlikilicer P, Rodriguez-Aguayo C, Pichler M, Bayraktar R, Bayraktar E, Ivan C, Filant J, Silva A, Aslan B, Denizli M, Mitra R, Ozpolat B, Calin GA, Sood AK, Abd-Ellah MF, Helal GK, Berestein GL. Rashed MH, et al. Among authors: bayraktar r, bayraktar e. Oncotarget. 2017 Mar 21;8(12):20145-20164. doi: 10.18632/oncotarget.15525. Oncotarget. 2017. PMID: 28423620 Free PMC article.
Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer.
Rodriguez-Aguayo C, Monroig PDC, Redis RS, Bayraktar E, Almeida MI, Ivan C, Fuentes-Mattei E, Rashed MH, Chavez-Reyes A, Ozpolat B, Mitra R, Sood AK, Calin GA, Lopez-Berestein G. Rodriguez-Aguayo C, et al. Among authors: bayraktar e. Cell Discov. 2017 Sep 12;3:17029. doi: 10.1038/celldisc.2017.29. eCollection 2017. Cell Discov. 2017. PMID: 28904816 Free PMC article.
Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models.
Kanlikilicer P, Ozpolat B, Aslan B, Bayraktar R, Gurbuz N, Rodriguez-Aguayo C, Bayraktar E, Denizli M, Gonzalez-Villasana V, Ivan C, Lokesh GLR, Amero P, Catuogno S, Haemmerle M, Wu SY, Mitra R, Gorenstein DG, Volk DE, de Franciscis V, Sood AK, Lopez-Berestein G. Kanlikilicer P, et al. Among authors: bayraktar r, bayraktar e. Mol Ther Nucleic Acids. 2017 Dec 15;9:251-262. doi: 10.1016/j.omtn.2017.06.023. Epub 2017 Jul 5. Mol Ther Nucleic Acids. 2017. PMID: 29246304 Free PMC article.
FABP4 as a key determinant of metastatic potential of ovarian cancer.
Gharpure KM, Pradeep S, Sans M, Rupaimoole R, Ivan C, Wu SY, Bayraktar E, Nagaraja AS, Mangala LS, Zhang X, Haemmerle M, Hu W, Rodriguez-Aguayo C, McGuire M, Mak CSL, Chen X, Tran MA, Villar-Prados A, Pena GA, Kondetimmanahalli R, Nini R, Koppula P, Ram P, Liu J, Lopez-Berestein G, Baggerly K, S Eberlin L, Sood AK. Gharpure KM, et al. Among authors: bayraktar e. Nat Commun. 2018 Jul 26;9(1):2923. doi: 10.1038/s41467-018-04987-y. Nat Commun. 2018. PMID: 30050129 Free PMC article.
PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer.
Hisamatsu T, McGuire M, Wu SY, Rupaimoole R, Pradeep S, Bayraktar E, Noh K, Hu W, Hansen JM, Lyons Y, Gharpure KM, Nagaraja AS, Mangala LS, Mitamura T, Rodriguez-Aguayo C, Eun YG, Rose J, Bartholomeusz G, Ivan C, Lee JS, Matsuo K, Frumovitz M, Wong KK, Lopez-Berestein G, Sood AK. Hisamatsu T, et al. Among authors: bayraktar e. Mol Cancer Ther. 2019 Jan;18(1):162-172. doi: 10.1158/1535-7163.MCT-17-1050. Epub 2018 Oct 10. Mol Cancer Ther. 2019. PMID: 30305341 Free PMC article.
Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.
Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, Rodriguez-Aguayo C, El-Arabey AA, Kahraman N, Baydogan S, Ozkayar O, Gatza ML, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G. Kanlikilicer P, et al. Among authors: bayraktar r, bayraktar e. EBioMedicine. 2018 Dec;38:100-112. doi: 10.1016/j.ebiom.2018.11.004. Epub 2018 Nov 25. EBioMedicine. 2018. PMID: 30487062 Free PMC article.
GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition.
Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, Sood AK. Ma S, et al. Among authors: bayraktar e. Mol Cancer Ther. 2019 May;18(5):969-979. doi: 10.1158/1535-7163.MCT-18-0770. Epub 2019 Mar 29. Mol Cancer Ther. 2019. PMID: 30926640 Free PMC article.
Identifying and targeting angiogenesis-related microRNAs in ovarian cancer.
Chen X, Mangala LS, Mooberry L, Bayraktar E, Dasari SK, Ma S, Ivan C, Court KA, Rodriguez-Aguayo C, Bayraktar R, Raut S, Sabnis N, Kong X, Yang X, Lopez-Berestein G, Lacko AG, Sood AK. Chen X, et al. Among authors: bayraktar r, bayraktar e. Oncogene. 2019 Aug;38(33):6095-6108. doi: 10.1038/s41388-019-0862-y. Epub 2019 Jul 9. Oncogene. 2019. PMID: 31289363 Free PMC article.
121 results